# Astellas Pharma Inc clinical trials: 525 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 525 trials with Astellas Pharma Inc as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Astellas Pharma Inc: 525 rows for $26.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/astellas-pharma-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 525
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 525, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 21, 2026 | NCT07829653 | A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause | Astellas Pharma Inc | Phase 3 | Recruiting | Hot Flashes | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829653) |
| January 6, 2026 | NCT07318714 | A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke | Astellas Pharma Inc | Phase 1/2 | Recruiting | Chronic Ischemic Stroke | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318714) |
| July 30, 2025 | NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Astellas Pharma Inc | Phase 1 | Recruiting | Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07094204) |
| May 14, 2025 | NCT06970665 | A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration | Astellas Pharma Inc | Phase 4 | Active not recruiting | Geographic Atrophy, Age-Related Macular Degeneration | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970665) |
| April 15, 2024 | NCT06364696 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | Astellas Pharma Inc | Phase 1 | Terminated | Solid Tumor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06364696) |
| January 16, 2024 | NCT06206421 | A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause | Astellas Pharma Inc | Phase 3 | Completed | Hot Flashes | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206421) |
| January 16, 2024 | NCT06206408 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause | Astellas Pharma Inc | Phase 3 | Completed | Hot Flashes | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206408) |
| December 5, 2023 | NCT06156696 | A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and... | Astellas Pharma Inc | Not applicable | Completed | Type 2 Diabetes Mellitus | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06156696) |
| July 14, 2022 | NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | Astellas Pharma Inc | Phase 2 | Terminated | Sentinel Lymph Node Biopsy, Breast Cancer, Melanoma | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05457842) |
| May 19, 2022 | NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | Astellas Pharma Inc | Phase 1 | Recruiting | Solid Tumor | 681 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05382559) |
| September 5, 2021 | NCT05034042 | A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause | Astellas Pharma Inc | Phase 2 | Completed | Hot Flashes | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05034042) |
| May 7, 2021 | NCT04878471 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants | Astellas Pharma Inc | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04878471) |
| November 24, 2020 | NCT04641962 | A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy | Astellas Pharma Inc | Phase 2 | Terminated | Primary Mitochondrial Myopathy | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04641962) |
| May 29, 2020 | NCT04408820 | Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia | Astellas Pharma Inc | Observational | Completed | Renal Anemia | 2,104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04408820) |
| January 23, 2020 | NCT04238481 | A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery | Astellas Pharma Inc | Phase 2 | Completed | Laparoscopic/Minimally Invasive Colorectal Surgery | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04238481) |
| December 11, 2019 | NCT04194697 | A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition | Astellas Pharma Inc | Not applicable | Completed | Healthy Volunteers | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04194697) |
| December 4, 2019 | NCT04184882 | A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne... | Astellas Pharma Inc | Phase 1 | Terminated | Duchenne Muscular Dystrophy (DMD) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04184882) |
| September 19, 2019 | NCT04094506 | Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors | Astellas Pharma Inc | Phase 1 | Completed | Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04094506) |
| June 3, 2019 | NCT03971253 | Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis | Astellas Pharma Inc | Observational | Completed | Rheumatoid Arthritis (RA) | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03971253) |
| May 10, 2019 | NCT03945253 | Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors | Astellas Pharma Inc | Phase 1 | Completed | Advanced Solid Tumors | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03945253) |
| May 8, 2019 | NCT03941483 | Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass... | Astellas Pharma Inc | Phase 2 | Completed | Acute Kidney Injury (AKI) | 351 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03941483) |
| August 22, 2018 | NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)... | Astellas Pharma Inc | Phase 4 | Completed | Metastatic Castration Resistant Prostate Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03641560) |
| August 10, 2018 | NCT03626207 | Development of Visual Function Evaluation Method (2) | Astellas Pharma Inc | Observational | Completed | Retinitis Pigmentosa | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03626207) |
| May 18, 2018 | NCT03528629 | A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | Astellas Pharma Inc | Not applicable | Completed | Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03528629) |
| March 21, 2018 | NCT03471728 | Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation... | Astellas Pharma Inc | Observational | Completed | Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases), Irritable Bowel Syndrome With Constipation... | 2,475 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03471728) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 147 |
| Phase 1/2 | 9 |
| Phase 2 | 110 |
| Phase 2/3 | 7 |
| Phase 3 | 140 |
| Phase 4 | 70 |
| Not applicable | 3 |
| Observational | 39 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 486 |
| Terminated | 32 |
| Recruiting | 4 |
| Withdrawn | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Urinary Bladder, Overactive | 42 |
| Diabetes Mellitus, Type 2 | 29 |
| Arthritis, Rheumatoid | 23 |
| Prostatic Neoplasms | 21 |
| Diabetes Mellitus | 19 |
| Dermatitis, Atopic | 16 |
| Renal Insufficiency, Chronic | 15 |
| Psoriasis | 14 |
| Urinary Incontinence | 13 |
| Renal Insufficiency | 13 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Neoplasms | 9 |
| Irritable Bowel Syndrome | 9 |
| Neoplasm Metastasis | 8 |
| Hyperphosphatemia | 8 |
| Ovarian Neoplasms | 8 |
| Sleep Initiation and Maintenance Disorders | 8 |
| Candidemia | 7 |
| Colorectal Neoplasms | 7 |
| Urinary Incontinence, Urge | 6 |
| Venous Thromboembolism | 6 |
| Prostatic Hyperplasia | 6 |
| Invasive Fungal Infections | 5 |
| Mycoses | 5 |
| Candidiasis | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Italian restaurants in the United States](https://specstream.ai/data/businesses/italian-restaurants/united-states)
- [Bistros in the United States](https://specstream.ai/data/businesses/bistros/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [European restaurants in the United States](https://specstream.ai/data/businesses/european-restaurants/united-states)
- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Litigation law firms in the United States](https://specstream.ai/data/businesses/litigation-law-firms/united-states)
